Digital smoking cessation company 2Morrow has partnered with GlaxoSmithKline, makers of Nicoderm patches, to offer the company’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
2Morrow’s smoking cessation app, called SmartQuit, is based on acceptance and commitment therapy, or an ACT-based program, that "focuses on increasing one’s willingness to accept the physical, mental...
The National Cancer Institute has awarded Jonathan Bricker, a behavioral scientist and faculty member at Fred Hutchinson Cancer Research Center, with a five-year, $3.1 million grant to conduct a randomized controlled trial of SmartQuit, a smoking-cessation app.
SmartQuit is based on acceptance and commitment therapy, or an ACT-based program, that "focuses on increasing one’s willingness to accept...
Seattle-based behavior change company 2Morrow has launched an app, called SmartQuit, that aims to help smokers quit.
2Morrow partnered with the Fred Hutchinson Cancer Research Center to create the app. In October, 2Morrow published a randomized control trial of 196 participants and found that users of SmartQuit were 2.5 to 3 times more likely to quit than those who try to quit on their own. The...
